Abstracts tagged "Biologic agents and remission"

Abstract Number: 1345 • 2019 ACR/ARP Annual Meeting
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Sadao Jinno¹, Akira Onishi ², Kengo Akashi ², Motomu Hashimoto ³, Wataru Yamamoto ³, Koichi Murata ³, Tohru Takeuchi ⁴, Takuya Kotani ⁴, Yuichi Maeda ⁵, Kosuke Ebina ⁶, Yonsu Son ⁷, Hideki Amuro ⁷, Ryota Hara ⁸, Masanori Katayama ⁹, Jun Saegusa ² and Akio Morinobu ², ¹Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Osaka, Japan, ²Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁴Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, ⁵Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, Osaka, Japan, ⁷First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, ⁸The Center for Rheumatic Disease, Department of Orthopedic Surgery, Nara Medical University, Nara, Japan, ⁹Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan
Background/Purpose: To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. Methods: Patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].